Most patients in a large integrated healthcare system who were high-risk for hospitalization were at substantially lower risk within 2 years.
The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
A chronic disease management company presents promising preliminary results from their remote intensive behavioral counseling intervention, aimed at addressing type 2 diabetes.
More consideration should be focused on consumer decision making and the quality and costs of acute care, and less attention should be paid to where care is delivered.
Complex care is cross-sector and person-centered, and it could bend America’s healthcare cost curve. The Blueprint for Complex Care gives this new field a national framework.
Even among practices reaching the highest level of PCMH achievement, there are variations in the implementation of key medical home capabilities.
Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
Recommendations from primary care Meaningful Use "exemplars" are that clinical quality measures likely to improve outcomes should be evidence-based, high priority, actionable, and minimize burden.
In primary care, nurse practitioners and physician assistants do not necessarily order more ancillary services, or more costly services among alternatives, than physicians.
A health insurance claims-based risk assessment tool to predict patients’ first severe chronic obstructive pulmonary disease exacerbation has been developed and validated.